Skip to main content

New, Noninvasive Paternity Test Developed

Identify the father of a baby as early as the eighth week of pregnancy.


The new method, reported in the New England Journal of Medicine, uses fetal DNA isolated from the mother's blood.

The test has already been used to prove an affair in a murder trial, and experts say it has other significant medical and legal applications.

"The technology is extremely important and really a very, very significant step forward for medical prenatal diagnosis," says Peter Benn, PhD, director of the diagnostic medical genetics laboratories at the University of Connecticut Health Center in Farmington. He was not involved in the research.

A previous study by the same researchers showed how the test could be used early in pregnancy to determine whether a fetus has Down syndrome, for example.
"That technology will allow genetic disorders to be identified without going through amniocentesis or chorionic villus sampling. That's a very important and useful step forward because those tests are not without some degree of risk to the fetus," Benn says.

Amniocentesis, in which a small sample of fluid that surrounds the fetus is removed and analyzed, and chorionic villus sampling, in which a small piece of tissue from the placenta is removed and analyzed, can cause infections, miscarriages, and birth defects. These tests are not able to be done before 10 to 15 weeks of pregnancy.
"Before we could only rely on tests that were invasive and could only be done later in pregnancy," says Jill Rabin, MD, chief of ambulatory care, obstetrics, and gynecology at Long Island Jewish Medical Center in New Hyde Park, N.Y.

"Here you have a blood test with the possibility of giving you an answer so that a woman can decide whether to proceed with a pregnancy or not based on the results of a noninvasive test. That is, right there, a tremendous utility," says Rabin, who was not involved in the research. "This is really cutting-edge stuff. It's very exciting."

Finding Fetal DNA in Mom's Blood

The new test overcomes several significant obstacles.

The first is that while researchers have long known that fetal DNA is present in the mother's blood, they believed it was floating around in such tiny amounts that it was almost impossible to find and analyze.

One of the reasons it was thought to be so rare, says researcher Ravinder Dhallan, MD, PhD, chairman and chief executive of Ravgen Diagnostics in Columbia, Md., is that the mother's blood cells easily burst when blood samples are drawn, which dilutes the fetal DNA.

By mixing a fixative agent into the blood sample, Dhallan says he was able to isolate enough fetal DNA so that it could be tested.

"What we realized was that if you add any fixative, it makes the mother's white blood cells, instead of being like water balloons that easily burst, they become more like ping pong balls that are stiff and won't burst," says Dhallan. "Now you've got 25% fetal DNA instead of 1% fetal DNA" in the blood.

 A sample of DNA from a suspected father can then confirm or exclude paternity.
By looking at the baby's DNA, researchers are able to spot places where the gene sequences are different from the mother's by only one letter. That letter will match the father's DNA.


When researchers tested 30 blood samples from biologic mothers and fathers who were grouped with unrelated men, they say they were able to correctly identify paternity in every case.

According to Ravgen's web site, the technology was used in 2009 to help prove that Michael A. Roseboro, who was on trial for his wife's murder, had fathered a baby with another woman. Prosecutors argued that the affair was motive for the murder.

Dhallen says he was motivated to develop the paternity test after being contacted by women who were eager to prove paternity and uncertain about whether to continue their pregnancies after situations involving violence, including
rape.

"There are so many situations where people need to identify the paternity before the baby is born that are social, medical, and legal," he says.

Source:
rxlist.com

Comments

Post a Comment

Popular posts from this blog

Final lunar eclipse of 2010 set for early morning of December 21

Skygazers hoping to catch the last lunar eclipse of 2010 on Tuesday morning best be ready to stay up late (or wake up very early) to watch the full moon as it goes through a range of dramatic color changes. The December 21 lunar eclipse is expected to last about three-and-a-half hours from its start as a partial eclipse at 1:33 a.m. ET to its finish at 5:01 a.m. ET, according to NASA. The previous lunar eclipse occurred June 26 . During a lunar eclipse, the moon, the Earth, and the sun align so that the sun's rays are shielded from the moon. An eclipse of the moon can only take place if the moon is full, and only if the moon passes through some portion of Earth's shadow, which is composed of two cone-shaped parts, one nested inside the other. The start of the total eclipse is expected around 2:41 a.m, when the entire moon passes through the Earth's umbra, or inner shadow, which blocks all direct sunlight from reaching the moon. The moon will tak...

Hand, Foot and Mouth Disease (HFMD) and Onychomadesis

  Introduction Nails are underutilized as diagnostic tools, despite being involved in many dermatologic conditions. This paper explores new concepts in the treatment of median nail dystrophy (MND), onychomycosis, and the nail pathology of hand, foot, and mouth disease (HFMD). A Pubmed database literature search was conducted for MND treatment, onychomycosis treatment, and HFMD nail pathology. Only papers published after January 2008 were reviewed. The results showed that 0.1% tacrolimus ointment can be an effective treatment for MND. Early studies on laser therapy indicate that it is a safe and efficacious treatment option for onychomycosis, compared to conventional oral antifungal agents. Vicks VapoRub (The Proctor & Gamble Company, Cincinnati, OH) is effective against onychomycosis and is a reasonable option in patients who choose to forgo conventional treatments. Lastly, there is evidence to support a correlation between HFMD and onychomadesis. ...

Men With Breast Cancer Face Worse Prognosis

Men who are diagnosed with breast cancer are more likely than female patients to die in the next 15 years, researchers report. "This may be due to a difference in tumor characteristics and treatment," says study leader Hui Miao, a PhD candidate at the National University of Singapore. Male breast cancer is rare, accounting for less than 1% of all breast cancers in the U.S. Given its scarcity, few studies have assessed its prognosis "and we know of no recent studies looking at trends in survival," Miao tells WebMD. So Miao and colleagues studied 459,846 women and 2,664 men diagnosed with breast cancer in Denmark, Finland, Switzerland, Norway, Singapore, and Sweden between 1970 and 2007. Among the findings, presented at the San Antonio Breast Cancer Symposium: Men were diagnosed at an older age: 69 vs. 61 for women. Twice as many men had later stage III or IV disease: 18% vs. 9% of women. Only 25% of men were alive 15 years after diagnosis, compared with 44...